Dr. Liebowitz has preclinical and clinical development experience in infectious diseases (virology), oncology, inflammation and metabolic disorders using vaccine, protein and small-molecule therapeutic modalities.  Before joining Vivaldi he was an independent consultant to the biotechnology and pharmaceutical industry.  Prior to that, he was Executive Vice President and Chief Scientific Officer at Galileo Pharmaceuticals, a small-molecule drug discovery and development company focused on inflammation and metabolic disorders.  He also served as Chief Executive Officer of Galileo.  Previously, Dr. Liebowitz was at Amgen, where he was the Director of Research, responsible for all oncology and vascular biology drug discovery and development programs at the Amgen Washington research site.  David joined Amgen through its acquisition of Immunex.  He was recruited to Immunex as a Medical Director in clinical development.  Later he moved within the Immunex organization to start a new research therapeutic area in oncology, where he was Senior Director, Cancer Biology and Therapeutic Development in Oncology.  Prior to joining Immunex, he was an Associate Investigator in the Abramson Cancer Institute at the University of Pennsylvania, where he served as Director of the immunotherapy and cellular therapy programs targeting chronic viral diseases and cancer.  He began his academic career as an Assistant Professor of Medicine and Virology at the University of Chicago, and was the Director of the Bone Marrow Transplantation Program.  His academic research focused on viral pathogenesis in immunosuppressed patients, and treatment and immunization strategies to prevent malignancies that develop in these patients as a result of viral infections.  Dr. Liebowitz was an early recipient of a grant from the Bill and Melinda Gates Foundation. He earned BS and MS degrees in Biology from Emory University, an MD with Honors and a PhD in Molecular Genetics and Cell Biology, both from the University of Chicago.